At a glance
A gonadotropin preparation with FSH and LH activity.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Fertility studies examine endpoints such as follicular development and sperm parameters under clinical monitoring. Their schedules depend on the treatment context and response.[3][4][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of HMG.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 0.15 mg + 75 IU · 1 source tables
Male Fertility Protocol (3 mL = 25 IU/mL)
| Week/Phase | Dose per Injection | Volume per Injection |
|---|---|---|
| Weeks 1–12 | 75 IU (0.15 mg) | 3.0 mL (300 units) |
| Weeks 13–16 (optional extension) | 75 IU (0.15 mg) | 3.0 mL (300 units) |
Frequency: Inject three times per week subcutaneously (for example, Monday, Wednesday, and Friday)[3][4]. HMG therapy is typically combined with hCG injections to maximize testosterone production and spermatogenesis[1][1]. Important Volume Note: Each full 75 IU dose requires 3.0 mL, which exceeds standard 1 mL insulin syringe capacity. Options include:
Additional schedule context & duration
Concise summary of the thrice-weekly male fertility regimen.
- Goal: Stimulate spermatogenesis in males with hypogonadotropic hypogonadism or infertility[3][4].
- Schedule: Subcutaneous injections three times weekly for minimum 12 weeks (extend to 16 weeks if needed)[7].
- Dose: 75 IU (0.15 mg) per injection, typically combined with hCG therapy[1][1].
- Reconstitution: 3.0 mL per 75 IU vial (25 IU/mL) for calculation convenience.
- Storage: Lyophilized refrigerated; reconstituted solution used promptly or within days when refrigerated.
Standard male fertility support approach.
- Dose: 75 IU three times per week (e.g., Monday, Wednesday, Friday).
- Combination Therapy: Usually administered alongside hCG (2–3 times weekly) to support testosterone and maximize spermatogenesis[1][1].
- Cycle Length: Minimum 12 weeks; may extend to 16 weeks based on response[7].
- Route: Subcutaneous injection into fatty tissue (abdomen, thigh, or upper arm)[2].
- Timing: Maintain consistent injection days; rotate sites with each injection.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile 3 mL syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll the vial until fully dissolved (do not shake).
- Label with date and time; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- For optimal potency, use reconstituted solution promptly or within a few days[2].
Storage Instructions
Proper storage maintains HMG stability and potency.
- Lyophilized (unopened): Store at 2–8 °C (35.6–46.4 °F) away from light; stable at controlled room temperature up to 25 °C (77 °F)[2].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); for best potency use promptly (official guidance recommends immediate use with plain diluent)[2].
- With bacteriostatic water, reconstituted solution may be refrigerated and used within a few days.
- Protect from light at all times; discard any unused solution if not used within recommended timeframe.
Injection Technique
Proper subcutaneous injection technique for HMG administration[2][5][5].
- Wash hands thoroughly and gather supplies on a clean surface.
- Clean the vial stopper with an alcohol swab and allow to dry.
- Draw up the prescribed dose using a sterile syringe (3 mL capacity for full 75 IU dose).
- Select an injection site with adequate subcutaneous fat (lower abdomen at least 2 inches from navel, outer thigh, or upper arm).
- Clean the injection site with a fresh alcohol swab; let dry completely.
- Pinch about an inch of skin to create a fold of subcutaneous tissue.
- Insert needle at a 90° angle (or 45° if very little subcutaneous fat) into the tissue[5][5].
- Release the pinch and slowly inject the medication over several seconds.
- Withdraw the needle smoothly and apply gentle pressure with sterile gauze (do not rub the site).
- Dispose of used syringe immediately in a sharps container[5].
- Rotate injection sites with each administration, maintaining at least 1 inch spacing from previous sites[5].
For Split-Dose Administration: If using 1 mL insulin syringes, divide the 3 mL total into three separate 1 mL injections at different sites (each containing 25 IU). Complete all three injections during the same administration session.
Materials & quantity planning
Source materials checklist · 0.15 mg + 75 IU
Plan based on a 12–16 week male fertility protocol with thrice-weekly administration.
-
Peptide Vials (HMG, 75 IU / 0.15 mg each):
- 12 weeks ≈ 36 vials (3 per week × 12 weeks)
- 16 weeks ≈ 48 vials (3 per week × 16 weeks)
-
Syringes (3 mL):
- Per week: 3 syringes (one per injection)
- 12 weeks: 36 syringes
- 16 weeks: 48 syringes
Note: If using 1 mL insulin syringes, multiply counts by 3 for split-dose administration.
-
Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.
- 12 weeks (36 vials): 108 mL → 4 × 30 mL bottles
- 16 weeks (48 vials): 144 mL → 5 × 30 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for each injection site.
- Per week: 6 swabs (2 per injection day)
- 12 weeks: 72 swabs → recommend 1 × 100-count box
- 16 weeks: 96 swabs → recommend 1 × 100-count box
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 06
Public health resource
Reproductive Medicine and Biology (2018) – Gonadotropin Therapy for Male Infertility — Review of hCG and hMG combination therapy for hypogonadotropic hypogonadism; FSH supplementation critical for spermatogenesis when hCG monotherapy inadequate (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.